Incidence and dose-volume analysis of acute bladder toxicity following pelvic radiotherapy

Tumori

Volumn 100, Issue 2, 2014, Pages 195-200

  Park, Jin Hong ^a   Kim, Young Seok ^a   Park, Jongmoo ^a   Ahn, Hanjong ^a   Kim, Choung Soo ^a   Kim, Minju ^a   Kim, Jong Hoon ^a   Ahn, Seung Do ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Acute bladder toxicity; Dose volume analysis; Radiotherapy

Indexed keywords

ACUTE TOXICITY; ADULT; AGED; ARTICLE; BLADDER DISEASE; BLADDER TOXICITY; BLADDER WALL; CANCER RADIOTHERAPY; COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS; COMPUTER ASSISTED RADIOTHERAPY; DOSIMETRY; FEMALE; HIGH RISK PATIENT; HISTOGRAM; HUMAN; INCIDENCE; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERACTIVE BLADDER SYMPTOM SCORE; PELVIC RADIOTHERAPY; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PELVIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; RECTAL NEOPLASMS; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; URINARY BLADDER; URINATION DISORDERS;

EID: 84901462394     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1491.16413     Document Type: Article

References (27)

1. Ahmed AA, Egleston B, Alcantara P, Li L, Pollack A, Horwitz EM, Buyyounouski MK: A novel method for predicting late genitourinary toxicity after prostate radiation therapy and the need for age-based risk-adapted dose constraints. Int J Radiat Oncol Biol Phys, 86: 709-715, 2013.
2. Ost P, Lumen N, Goessaert AS, Fonteyne V, De Troyer B, Jacobs F, De Meerleer G: High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results. Eur Urol, 60: 842-849, 2011.
3. Barry MJ, Fowler FJ, Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT: The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol, 148: 1549-1564, 1992.
4. Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamanishi T, Yamaguchi O, Takeda M, Nishizawa O: Symptom assessment tool for overactive bladder syndrome - overactive bladder symptom score. Urology, 68: 318-323, 2006. (Pubitemid 44175525)
5. Choi HJ, Kim YS, Lee SH, Lee YS, Park G, Jung JH, Cho BC, Park SH, Ahn H, Kim CS, Yi SY, Ahn SD: Inter- and intra-observer variability in contouring of the prostate gland on planning computed tomography and cone beam computed tomography. Acta Oncol, 50: 539-546, 2011.
6. Kim YS, Kim JH, Ahn SD, Lee SW, Shin SS, Nam JH, Kim YT, Kim YM, Kim JH, Choi EK: High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys, 74: 1522-1528, 2009.
7. Kim YS, Shin SS, Nam JH, Kim YT, Kim YM, Kim JH, Choi EK: Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. Gynecol Oncol, 108: 195-200, 2008. (Pubitemid 350299446)
8. Park JH, Yoon SM, Yu CS, Kim JH, Kim TW, Kim JC: Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. Cancer, 117: 3703-3712, 2011.
9. Small W, Jr, Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, Jhingran A, Portelance L, Schefter T, Iyer R, Varia M, Winter K, Mundt AJ: Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys, 71: 428-434, 2008. (Pubitemid 351636192)
10. Roach M, 3rd, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UO, Navvab Z, Carroll PR: Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys, 28: 33-37, 1994. (Pubitemid 24012852)
11. Harsolia A, Vargas C, Yan D, Brabbins D, Lockman D, Liang J, Gustafson G, Vicini F, Martinez A, Kestin LL: Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study. Int J Radiat Oncol Biol Phys, 69: 1100-1109, 2007. (Pubitemid 47625853)
12. Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys, 31: 1341-1346, 1995.
13. De Meerleer G, Vakaet L, Meersschout S, Villeirs G, Verbaeys A, Oosterlinck W, De Neve W: Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys, 60: 777-787, 2004. (Pubitemid 39311757)
14. Karlsdottir A, Johannessen DC, Muren LP, Wentzel-Larsen T, Dahl O: Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiother Oncol, 71: 43-53, 2004. (Pubitemid 38452901)
15. Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PC: Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys, 61: 1019-1034, 2005. (Pubitemid 40340897)
16. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA: High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys, 53: 1111-1116, 2002. (Pubitemid 34787844)
17. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Jr, Miller DW, Adams JA, Shipley WU: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA, 294: 1233-1239, 2005. (Pubitemid 41352111)
18. Valicenti RK, Winter K, Cox JD, Sandler HM, Bosch W, Vijayakumar S, Michalski J, Purdy J: RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? Int J Radiat Oncol Biol Phys, 57: 614-620, 2003. (Pubitemid 37194286)
19. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I: Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys, 48: 635-642, 2000.
20. Alongi F, Fiorino C, Cozzarini C, Broggi S, Perna L, Cattaneo GM, Calandrino R, Di Muzio N: IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol, 93: 207-212, 2009.
21. Cheng JC, Schultheiss TE, Nguyen KH, Wong JY: Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys, 71: 351-357, 2008.
22. Deville C, Vapiwala N, Hwang WT, Lin H, Ad VB, Tochner Z, Both S: Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys, 82: 1389-1396, 2012.
23. Koper PC, Stroom JC, van Putten WL, Korevaar GA, Heijmen BJ, Wijnmaalen A, Jansen PP, Hanssens PE, Griep C, Krol AD, Samson MJ, Levendag PC: Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys, 43: 727-734, 1999. (Pubitemid 29152645)
24. Lebesque JV, Bruce AM, Kroes AP, Touw A, Shouman RT, van Herk M: Variation in volumes, dose-volume histograms, and estimated normal tissue complication probabilities of rectum and bladder during conformal radiotherapy of T3 prostate cancer. Int J Radiat Oncol Biol Phys, 33: 1109-1119, 1995.
25. Mohammed N, Kestin L, Ghilezan M, Krauss D, Vicini F, Brabbins D, Gustafson G, Ye H, Martinez A: Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys, 82: 204-212, 2012.
26. Pollack A, Zagars GK, Starkschall G, Childress CH, Kopplin S, Boyer AL, Rosen II: Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys, 34: 555-564, 1996. (Pubitemid 26069185)
27. Teh BS, Mai WY, Uhl BM, Augspurger ME, Grant WH, 3rd, Lu HH, Woo SY, Carpenter LS, Chiu JK, Butler EB: Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis. Int J Radiat Oncol Biol Phys, 49: 705-712, 2001. (Pubitemid 32114105)